Filing Flows › Comparisons › PROK vs CRDF
Prokidney vs Cardiff Oncology: PROK and CRDF compared
Prokidney is the larger company: $150K of revenue in its latest quarter (Q2 2026) against $104K for Cardiff Oncology (Q2 2026). Cardiff Oncology is growing faster (-14% against -32% a year earlier).
Where the money goes: PROK and CRDF
Prokidney (PROK) · Q2 2026
Prokidney, Q2 2026: revenue $150K (-32% year over year), net loss $46.4M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
Cardiff Oncology (CRDF) · Q2 2026
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Prokidney (PROK) | Cardiff Oncology (CRDF) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $150K | $104K |
| Revenue growth, Y/Y | -32% | -14% |
| Operating margin | n/m | n/m |
| Net earnings | −$46.4M | −$9.2M |
| Operating cash flow | −$40.4M | −$11.8M |
Questions
Which is bigger, Prokidney or Cardiff Oncology?
Prokidney is the larger company: $150K of revenue in its latest quarter (Q2 2026) against $104K for Cardiff Oncology (Q2 2026).
Is Prokidney or Cardiff Oncology growing faster?
Cardiff Oncology is growing faster (-14% against -32% a year earlier).
More: Prokidney earnings · how Prokidney makes money · Cardiff Oncology earnings · how Cardiff Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.